Retatrutide, sammenfatning af evidensgrundlaget Vi ved: Fase 2 viser 24,2% vgttab ved 12 mg over 48 uger (NEJM 2023) Fase 3 TRIUMPH-1, det pivotale fedme-studie (2.339 deltagere), viser 28,3% over 80 uger, op til 30,3% ved 104-ugers forlngelse hos BMI35 (forr 2026) Fase 3 TRIUMPH-4 (knartrose-substudie) viser 28,7% over 68 uger (december 2025) Bivirkningsprofilen ligner semaglutide og tirzepatide Leverfedtreduktion p op til 82% i substudie Markant HbA1c-reduktion ved type 2-diabetes (Lancet 2023) Vi ved endnu ikke: Langsigtet sikkerhed ud over 68 uger Prcis effekt p muskelmasse Kardiovaskulrt outcome (TRIUMPH-3 afventer) Effekt ved ophr Endelig pris og tilskudsstatus i Danmark Retatrutide og mental sundhed, en overset dimension Fedme og mental sundhed er tt forbundne
Key findings include: Mean weight loss of 24.2% (approximately 58 pounds or 26.2 kg) with 12 mg weekly dose after 48 weeks Dose-dependent efficacy across 1 mg, 4 mg, 8 mg, and 12 mg dose groups At 48 weeks, 100% of participants receiving 8 mg or 12 mg achieved at least 5% weight loss 93% of participants on 12 mg achieved 15% or more weight loss , far exceeding current therapeutic benchmarks Greater weight reduction observed in participants with BMI greater than or equal to 35 compared to those with BMI below 35 The magnitude of weight loss approaches that typically observed only with bariatric-metabolic surgery, representing a potential paradigm shift in pharmacological obesity treatment[11]
Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis
Gateva P, Hristov M, Ivanova N, Vasileva D, Ivanova A, Sabit Z, Bogdanov T, Apostolova S, Tzoneva R (2024) Antinociceptive behavior, glutamine/glutamate, and neopterin in early-stage streptozotocin-induced diabetic neuropathy in liraglutide-treated mice under a standard or enriched environment
Treatment with metformin 2000 mg/day and promotion of lifestyle intervention were continued during the 2-year follow-up period
.png)
